Our portfolio of pharma-sponsored trials provides local access to promising investigational therapies.
Expanded treatment selection across therapy classes
Combined DNA and quantitative RNA profiling from limited tumor tissue provides the opportunity for treatment with a broader range of therapeutic modalities.
Strata Select™ is a pan-solid tumor molecular profiling test for patients with advanced cancer that provides treatment selection guidance for immunotherapy and beyond.
Longitudinal disease monitoring across all disease stages
Ultra-sensitive ctDNA-based recurrence and treatment response monitoring informs treatment decisions throughout the patient care journey.
One tissue sample powers comprehensive treatment selection and personalized liquid-biopsy based monitoring through Strata Sentinel.
Local access to more precision treatments
Strata PATH™ is a multi-arm platform trial testing novel treatment hypotheses for existing FDA-approved therapies across multiple tumor types.
A range of therapeutic classes will be evaluated in Strata PATH™ including targeted therapies, antibody-drug conjugates, immunotherapies and angiogenesis inhibitors.
Customized service and support
Strata Oncology provides the infrastructure and expertise to deliver precision cancer care to large populations.
- Dedicated customer success team
- Clinical education and consults
- Customized workflows
- Research support and partnership
